Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myconostica CE marks Aspergillus assay

This article was originally published in Clinica

Executive Summary

UK diagnostics firm Myconostica has CE marked its MycAssay Aspergillus test for sale in Europe. The diagnostic uses real-time PCR to identify the genus of fungus, one of the most common causes of fungal pneumonia. It could improve patient survival, as it can provide results within three hours – when used with Myconostica's fungal DNA extraction system, MycXtra – compared with up to 10 days for conventional methods. Diagnosis of Aspergillus infection and subsequent antifungal treatments within 10 days reduces mortality from 90% to 40%. Pneumonia caused by Aspergillus is the leading cause of infectious death in leukaemia and bone marrow cancer patients, with around 10 million people at risk each year worldwide, the Manchester-based company estimates.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel